Literature DB >> 11216406

Safety of simultaneous resections of colorectal cancer and liver metastases.

M Doko1, M Zovak, M Ledinsky, A Mijić, M Perić, M Kopljar, R Culinović, B Rode, B Doko.   

Abstract

Liver resection is the only potentially curative method for patients with colorectal cancer metastases and 5-year survival rates are 20%-40%. Simultaneous resection of colorectal cancer and synchronous liver metastases has been recommended if minor hepatectomy is indicated. The purpose of this paper is to analyze the treatment of hepatic colorectal secondaries and to assess the safety of simultaneous and delayed liver resections and relations of morbidity to the extensiveness of hepatectomy and perioperative factors. Analyzed were 21 patients with liver metastases from colorectal cancer operated between 1997 and 1999 in the Clinical Hospital "Sestre milosrdnice". Operating time for simultaneous colorectal and liver resections was not significantly longer compared to liver resections alone. No significant difference in complication rate was found after simultaneous procedures and liver resection alone (38% vs. 31%). Complication rate after major liver resections was not significantly greater than after minor resections (38% vs. 31%). No statistically significant differences were found in operation time and blood replacement between patients who developed postoperative complications and those who did not. In conclusion, simultaneous resections of primary colorectal cancer and liver metastases may be considered safe. Morbidity rates are not significantly different from those after liver resections alone, nor depend significantly upon the extensiveness of liver resection, providing that the operation time and blood loss are within the range observed in this study.

Entities:  

Mesh:

Year:  2000        PMID: 11216406

Source DB:  PubMed          Journal:  Coll Antropol        ISSN: 0350-6134


  6 in total

Review 1.  Potential use of Doppler perfusion index in detection of occult liver metastases from colorectal cancer.

Authors:  Mario Kopljar; Leonardo Patrlj; Zeljko Bušić; Marijan Kolovrat; Mislav Rakić; Robert Kliček; Marcel Zidak; Igor Stipančić
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases.

Authors:  Eduardo de Santibañes; Diego Fernandez; Carlos Vaccaro; Guillermo Ojea Quintana; Fernando Bonadeo; Juan Pekolj; Carlos Bonofiglio; Ernesto Molmenti
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

3.  Practical questions in liver metastases of colorectal cancer: general principles of treatment.

Authors:  Héctor Daniel González; Joan Figueras
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

4.  Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.

Authors:  Sarah Y Boostrom; David M Nagorney; John H Donohue; Scott Harmsen; Kristine Thomsen; Florencia Que; Michael Kendrick; Kaye M Reid-Lombardo
Journal:  J Gastrointest Surg       Date:  2009-09-16       Impact factor: 3.452

5.  Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases.

Authors:  Peter J Allen; Nancy Kemeny; William Jarnagin; Ronald DeMatteo; Leslie Blumgart; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

6.  Optimizing clinical and economic outcomes of surgical therapy for patients with colorectal cancer and synchronous liver metastases.

Authors:  Daniel E Abbott; Scott B Cantor; Chung-Yuan Hu; Thomas A Aloia; Y Nancy You; Sa Nguyen; George J Chang
Journal:  J Am Coll Surg       Date:  2012-05-04       Impact factor: 6.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.